Yervoy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Conditions:   Oncology;   Infusion Reaction Interventions:   Drug: Nivolumab;   Drug: Pembrolizumab;   Drug: Ipilimumab;   Drug: Durvalumab;   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: Trastuzumab Sponsor:   Isala Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials